SCYNEXIS(US:SCYX) Globenewswire·2026-02-26 13:23Core Insights - SCYNEXIS, Inc. has initiated a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial for its intravenous formulation of SCY-247, an antifungal therapy aimed at treating invasive candidiasis and preventing invasive fungal diseases, with results expected in 2026 [1][2] Group 1: Company Developments - The first participants have been dosed in the Phase 1 trial of SCY-247, which has received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA, indicating its potential significance in treating severe fungal infections [2][3] - SCY-247's oral formulation has shown positive results in previous SAD/MAD data, demonstrating excellent pharmacokinetic and pharmacodynamic properties, achieving target exposures at lower doses than first-generation antifungals [2] - The company is exploring non-dilutive funding opportunities to support the SCY-247 program, highlighting its commitment to addressing health security threats posed by antifungal resistance [2] Group 2: Product Information - SCY-247 is part of SCYNEXIS's proprietary antifungal platform "fungerps," which includes Ibrexafungerp, already approved for treating vulvovaginal candidiasis [4] - The second-generation fungerp SCY-247 is currently in clinical development stages, with additional antifungal assets from this class in pre-clinical and discovery phases [4]